In keeping with this model, the association of the increase in IL-10 with disease severity may indicate that the anti-inflammatory properties of IL-10 contribute to lung protection and virus replication not only in the pre-clinical phase, but that this cytokine may still be double-dealing in the critical phase of COVID-19 although its blood levels are already slowly declining. The gene discussed is IL10; the disease is COVID-19.